Evaluation of CNS-Active Drugs for Worldwide Submission

 

In this complimentary webinar, Dr. Beatrice Setnik and Dr. Andy Mead take a comprehensive look at the key differences between the EMA and FDA drug development requirements when evaluating CNS-active drugs for abuse potential, as well as the need for a controlled substance designation.

Watch the webinar.

Questions? Speak with our scientists.

You may also be interested in the following:

• Podcast: Altasciences' Scientific Experts Discuss Safety Pharmacology
• Webinar: Navigating Early Phase CNS-Active Drug Development
• Fact Sheet: Driving Simulation Studies
• Webpages:
  • Project Management
  • Tell Us Once™

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.